Overview

• A blood test detecting eMTBR-tau243 has shown superior accuracy in diagnosing Alzheimer’s and tracking its progression compared to current methods.
• The test could help identify patients suitable for new Alzheimer’s drugs, such as donanemab and lecanemab, which are most effective in early stages.
• Researchers report the test correlates tau protein fragments in blood with cognitive impairment and tau tangles in the brain, hallmarks of Alzheimer’s.
• Despite its promise, the test is limited to specialized laboratories and requires further validation and simplification for widespread clinical use.
• Complementary research has identified additional biomarkers, such as the YWHAG:NPTX2 protein ratio, which could predict cognitive decline and dementia onset.